Life Science Investing Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers
pharmaceutical investing Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke
Locksley Resources Announces Significant Expansion of its Exploration Program for both Rare Earths and Antimony After Increasing its Landholding to More than 40 Square Kilometers in California's Mojave Region
